Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting

European Journal of Pharmacology

Volumn 722, Issue 1, 2014, Pages 180-186

  Navari, Rudolph M ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer treatment; Chemotherapy; Emesis; Nausea; Olanzapine

Indexed keywords

ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANISETRON; IRINOTECAN; MEGESTROL ACETATE; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; PALONOSETRON; PLATINUM COMPLEX; SEROTONIN 2C RECEPTOR; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ANTIEMETIC ACTIVITY; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SEDATION; WEIGHT GAIN;

CANCER TREATMENT; CHEMOTHERAPY; EMESIS; NAUSEA; OLANZAPINE;

ANIMALS; BENZODIAZEPINES; CHRONIC DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NAUSEA; VOMITING;

EID: 84892866390     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.08.048     Document Type: Review

References (42)

1. 3 antagonist plus dexamethasone in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study J. Clin. Oncol. 30 2012 3998 4003
2. D.B. Allison, and D.E. Casey Antipsychotic-associated weight gain: a review of the literature J. Clin. Psychiatry 62 2001 22 31
3. E. Basch, A.A. Prestrud, P.J. Hesketh, M.G. Kris, P.C. Fever, M.R. Somerfield, M. Chesney, R.A. Clark-Snow, A.M. Flaherty, B. Freunlich, G. Morrow, K.V. Rao, R.N. Schwartz, and G.H. Lyman Antiemetic American Society Clinical Oncology clinical practice guideline update J. Clin. Oncol. 29 2011 4189 4198
4. B. Bloechl-Daum, R.R. Deuson, P. Mavros, M. Hansen, and J. Herrstedt Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment J. Clin. Oncol. 24 2006 4472 4478
5. W. Breithart, A. Tremblay, and C. Gibson An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients Psychosomatics 43 2002 175 182
6. F.P. Bymaster, D. Calligaro, J. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
7. F.P. Bymaster, J.F. Falcone, D. Bauzon, J.S. Kennedy, K. Schenck, N.W. DeLapp, and M.L. Cohen Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine Eur. J. Pharmacol. 430 2001 341 349
8. M.P. Curran, and D.M. Robinson Aprepitant: a review of its use in the prevention of nausea and vomiting Drugs 69 2009 1853 1858
9. L.H. Einhorn, M.L. Brames, R. Dreicer, C.R. Nichols, M.T. Cullen, and J. Bubalo Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer Support Care Cancer 15 2007 1293 1300
10. B. Fulton, and K.L. Goa Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses Drugs 53 1997 281 298
11. L.E. Goldstein, J. Sporn, S. Brown, H. Kim, J. Finkelstein, G.K. Gaffey, G. Sachs, and T.A. Stern New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment Psychosomatics 40 1999 438 443
12. A.S. Hale Olanzapine Br. J. Hosp. Med. 58 1997 443 445
13. K.M. Hurren, and H.D. Berlie Lorcaserin: an investigational serotonin 2C agonist for weight loss Am. J. Health Syst. Pharm. 68 2011 2029 2037
14. W.C. Jackson, and L. Tavernier Olanzapine for intractable nausea in palliative care patients J. Palliative Med. 6 2003 251 255
15. J.C. Kando, J.C. Shepski, W. Satterlee, J.K. Patel, S.G. Rearns, and A.L. Green Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia Ann. Pharmacother. 31 1997 1325 1334
16. N. Khojainova, J. Santiago-Palma, C. Kornick, W. Breitbart, and G.R. Gonzales Olanzapine in the management of cancer pain J. Pain Symptom Manage. 23 2002 546 550
17. K.S. Kim, C.U. Pae, J.H. Chae, W.M. Bahk, and T. Jun An open pilot trial of olanzapine for delirium for the Korean population Psychiatry Clin. Neurosci. 55 2001 515 519
18. K. Kaneishi, M. Kawabara, and T. Morita Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction J. Pain Symptom Manage. 44 2012 604 607
19. M.C. Kris Why do we need another antiemetic? Just ask J. Clin. Oncol. 21 2003 4077 4080
20. N. Licup, and S. Baumrucker Olanzapine for nausea and vomiting Am. J. Hosp. Palliat. Care 27 2010 432 434
21. J.C. Lundberg, and S. Passik Controlling opioid-induced nausea with olanzapine Primary Care Cancer 20 2000 35 37
22. R.M. Navari Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents Drugs 73 2013 249 262
23. R.M. Navari Prevention of emesis from multiple-day chemotherapy regimens J. Nat. Compr. Cancer Netw. 5 2007 51 59
24. R.M. Navari Treatment of chemotherapy-induced nausea Community Oncol 9 2012 20 26
25. R.M. Navari Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer Future Oncol. 6 2010 1074 1084
26. R.M. Navari, L.H. Einhorn, P.J. Loehrer, S.D. Passik, J. Vinson, J. McClean, N. Chowhan, N.H. Hanna, and C.S. Johnson A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting Support Care Cancer 15 2007 1285 1291
27. R.M. Navari, L.H. Einhorn, S.D. Passik, P.J. Loehrer, C. Johnson, M.L. Mayer, J. McClean, J. Vinson, and W. Pletcher A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting Support Care Cancer 13 2005 529 534
28. Navari, R.M., Gray, S.E., Kerr, A.C., 2011. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J. Support Oncol. 9, 188-195.
29. R.M. Navari, C.K. Nagy, and S.E. Gray Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Support Care Cancer 21 2013 1655 1663
30. S.D. Passik, K.L. Kirsh, D.E. Theobald, P. Dickerson, R. Trowbridge, D. Gray, M. Beaver, J. Comparet, and J. Brown A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients J. Pain Symptom Manage. 25 2003 485 489
31. S.D. Passik, J. Lundberg, K.L. Kirsh, D. Theobald, K. Donagby, E. Holtschaw, M. Cooper, and W. Dugan Clinical note: a pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced pain and cancer J. Pain Symptom Manage. 23 2002 526 532
32. S. Passik, R.M. Navari, S.H. Jung, C.K. Nagy, J. Vinson, K.L. Kirsh, and P.J. Loehrer A phase I trial of olanzapine for the prevention of delayed emesis in cancer patients receiving chemotherapy Cancer Invest. 22 2004 383 388
33. W.F. Pirl, and A.J. Roth Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report Psychooncology 9 2000 84 87
34. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, L.H. Einhorn, E. Ballatori, E. Bria, R.A. Clark-Snow, B.T. Espersen, P. Feyer, S.M. Grunberg, P.J. Hesketh, K. Jordan, M.G. Kris, A. Maranzano, G. Morrow, I. Oliver, B.L. Rapoport, C. Rittenberg, M. Saito, M. Tonato, and D. Warr Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann. Oncol. 21 2010 232 243
35. J.A. Rudd, M.P. Ngan, M.K. Wai, A.G. King, J. Witherington, P.L. Andrews, and G.J. Sanger Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin Neurosci. Lett. 392 2006 79 83
36. K.K. Sankhala, D.M. Pandya, J. Sarantopoulos, S.A. Soefie, F.J. Giles, and S.P. Chawla Prevention of chemotherapy-induced nausea and vomiting: a focus on aprepitant Expert Opin. Drug Metab. Toxicol. 12 2009 1607 1614
37. M. Srivastava, N. Brito-Dellan, M.P. Davis, M. Leach, and R. Lagman Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer J. Pain Symptom Manage. 25 2003 578 582
38. C.M.E. Stephenson, and L.S. Pilowsky Psychopharmacology of olanzapine: a review Br. J. Psychiatry 174 1999 52 58
39. R.M. Stern, K.L. Koch, and P.L.R. Andrews Nausea: Mechanisms and Management 2011 Oxford New York NY
40. L. Tan, J. Liu, X. Liu, J. Chen, Z. Yan, H. Yang, and D. Zhang Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting J. Exp. Clin. Cancer Res. 28 2009 1 7
41. Y.C. Tina Shih, Y. Xu, and L.S. Elting Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Cancer 110 2007 678 685
42. K. Yakabi, C. Sadakane, M. Noguchi, S. Ohno, R. Shoki, K. Chinen, T. Aoyanna, T. Sakurada, H. Takabayashi, and T. Hattori Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia Endocrinology 151 2010 3773 3782